^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    2d
    Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study. (PubMed, JTO Clin Res Rep)
    Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. mOS and mPFS were not significantly different between SCLC subtypes but were numerically shorter in the SCLC-N group. CD8+ TIL density is a potential biomarker of clinical benefit in ES-SCLC and may facilitate patient selection for atezolizumab combination therapy.
    Observational data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV
    2d
    A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • RET fusion • ALK fusion • ALK mutation • RET mutation • ROS1 fusion • EGFR positive • NTRK fusion
    |
    Avastin (bevacizumab) • etoposide IV • utidelone IV (UTD1)
    2d
    A Study of FZ-AD005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=162, Recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • First-in-human
    2d
    Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer. (PubMed, J Transl Med)
    Our findings provide a comprehensive understanding of the lineage plasticity and the immune landscape in T-SCLC, highlighting the crucial role of the stem-like cell cluster and ISG+ lymphocytes in LUAD-to-SCLC transformation.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    2d
    Analysis of Acquired Fusion Mutations in EGFR-TKIs-Resistant Patients with Advanced Lung Cancer. (PubMed, J Coll Physicians Surg Pak)
    One patient with acquired fusion gene mutations developed small-cell lung cancer transformation after ALK-TKIs resistance. Key Words: Lung cancer, ALK fusion, RET fusion, ROS1 fusion, EGFR-TKIs-resistance, Targeted therapy.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • RET fusion • ALK fusion • RET mutation • ROS1 fusion
    2d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, BioNTech SE | N=26 --> 52
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    3d
    5-STAR 1-01: First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=250, Recruiting, Tubulis GmbH | N=130 --> 250
    Enrollment change • First-in-human
    3d
    DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imdelltra (tarlatamab-dlle)
    3d
    MRT-2359-001: Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=174, Active, not recruiting, Monte Rosa Therapeutics, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    HR positive • HER-2 negative • MYCN amplification
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    4d
    Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. (clinicaltrials.gov)
    P3, N=134, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P3 trial
    |
    Focus V (anlotinib)
    4d
    Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations. (PubMed, J Pathol)
    © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • AKR1C1 (Aldo-Keto Reductase Family 1 Member C1) • AKR1B10 (Aldo-Keto Reductase Family 1 Member B10)
    |
    TMB-H • KEAP1 mutation • NFE2L2 mutation
    4d
    Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport. (PubMed, Cancer Sci)
    In mouse xenograft models, PANX1 knockdown suppressed, whereas PANX1 overexpression enhanced, tumor growth in vivo. These findings indicate that SCLC exploits a PANX1-dependent ATP release mechanism to engage P2RX7-mediated autocrine signaling and suggest that targeting this axis may represent a potential therapeutic opportunity for this lethal cancer.
    Journal
    |
    TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1)